Kuhnil to concentrate marketing on Gliadelwaper business.

Kuhnil announced that the company would concentrate a whole effort to the market development of Gliadelwaper, a first choice of drug for the malignant glioma patients.

The company said Gliadelwaper is a locally implanting type of the radioactive therapeutic drugs into the tumor site by a single or in combination with other chemotherapy, which is only an implanting anti-cancer drug without a...